Phase 3
N=310
Safety Study of a Contact Lens With Ketotifen in Healthy, Normal Volunteers
Allergic Conjunctivitis
Bottom Line
View on ClinicalTrials.gov: NCT00569777 ↗Enrolled (actual)
310
Serious AEs
0.7%
Results posted
Nov 2010
Primary outcome: Primary: Lid and Lid Margin Erythema, Change From Baseline — 0; 0 Units on a scale
Study Design & Population
- Study type
- Interventional
- Phase
- Phase 3
- Interventions
- K-Lens (generic name not established) and Ketotifen (Device); Placebo Lens (Device)
- Age
- Pediatric, Adult, Older Adult · 8+ yrs
- Sex
- All
- Sponsor
- Vistakon Pharmaceuticals
- Primary completion
- Feb 2008
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Lid and Lid Margin Erythema, Change From Baseline |
0; 0 | — |
| PRIMARY Lid and Lid Margin Swelling, Change From Baseline |
0; 0 | — |
| PRIMARY Conjunctival Redness, Change From Baseline |
0; -0.1 | — |
| PRIMARY Conjunctival Chemosis, Change From Baseline |
0; 0 | — |
| PRIMARY Corneal Edema, Change From Baseline |
0; 0 | — |
| PRIMARY Corneal Erosion, Change From Baseline |
0; 0 | — |
| PRIMARY Corneal Endothelial, Change From Baseline |
0; 0 | — |
| PRIMARY Lens Pathology, Change From Baseline |
0; -0.1 | — |
| PRIMARY Flare in Anterior Chamber, Change From Baseline |
0; 0 | — |
| PRIMARY Cells in Anterior Chamber, Change From Baseline |
0; 0 | — |
| PRIMARY Corneal Staining - Nasal, Change From Baseline |
-0.1; 0 | — |
| PRIMARY Corneal Staining - Temporal, Change From Baseline |
0; 0 | — |
| PRIMARY Corneal Staining - Inferior, Change From Baseline |
0; 0 | — |
| PRIMARY Corneal Staining - Superior, Change From Baseline |
0; 0 | — |
| PRIMARY Corneal Staining - Central, Change From Baseline |
0; 0 | — |
| PRIMARY Intraocular Pressure, Change From Baseline |
-0.3; -0.4 | — |
| PRIMARY Dilated Ophthalmoscopy - Fundus, Change From Baseline |
-0.1; 0 | — |
| PRIMARY Dilated Ophthalmoscopy - Vitreous, Change From Baseline |
0; 0 | — |
| PRIMARY Visual Acuity Assessment |
362; 178 | — |
Summary
The purpose of this study is to evaluate the safety of a novel contact lens in healthy normal volunteers
Eligibility Criteria
Inclusion Criteria
- healthy normal, soft contact lens wearing volunteers
- normal ocular health
- contact lens correction from +6.00 to -12.00D in each eye and astigmatism of -1.00D or less in each eye
Exclusion Criteria
- active ocular infection
- history of ocular surgery
- use of topical ophthalmic preparations (including rewetting drops)
- pregnancy or lactation
Data sourced from ClinicalTrials.gov (NCT00569777). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.